ZEB2 and breast carcinoma: The breast cancer basal-like subtype-specific miRNAs, miR-221 and miR-222, promote EMT in breast cancer by targeting TRPS1 (trichorhinophalangeal syndrome type 1) which inhibits EMT by repressing ZEB2 expression [38].